

Supplementary Table 2: Parametric synergy analysis using MuSyC and BRAID models to assess the relationship between gartisertib, TMZ and RT within glioblastoma cell lines

Cell line	MuSyC analysis											BRAID analysis				
	Efficacy ^a				→ TMZ potency ^b			→ RT potency ^c			→ Gartisertib potency ^d			Kappa		
	TMZ + RT	Gartisertib + TMZ	Gartisertib + RT	Gartisertib + TMZ + RT	RT	Gartisertib	Gartisertib+RT	TMZ	Gartisertib	Gartisertib+TMZ	TMZ	RT	TMZ+RT	TMZ + RT	Gartisertib + TMZ	Gartisertib + RT
HW1	Ant	Ant	Ant	Ant	Ant	Ant	Syn	Ant	Syn	Ant	Syn	Ant	Ant	Syn	Ant	
FPW1	Ant	Ant	Ant	Syn	Syn	Syn	Syn	Ant	Syn	Syn	Syn	Ant	Syn	Syn	Syn	
JK2	Ant	Ant	Syn	Ant	Ant	Ant	Syn	Ant	Syn	Ant	Syn	Syn	Ant	Syn	Syn	
BAH1	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Ant	Syn	Ant	
RKII	Ant	Ant	Ant	Ant	Ant	Syn	Ant	Syn	Ant	Syn	Syn	Syn	Ant	Syn	Syn	
MMK1	Ant	Ant	Ant	Ant	Syn	Syn	Ant	Ant	Ant	Syn	Syn	Ant	Ant	Syn	Syn	
SJH1	Syn	Ant	Syn	Ant	Ant	Syn	Ant	Ant	Syn	Ant	Syn	Syn	Ant	Syn	Ant	
WK1	Ant	Ant	Ant	Ant	Ant	Syn	Syn	Ant	Syn	Syn	Syn	Ant	Ant	Syn	Syn	
RN1	Ant	Syn	Syn	Syn	Syn	Syn	Ant	Syn	Syn	Syn	Syn	Syn	Ant	Syn	Syn	
SB2b	Ant	Ant	Ant	Syn	Ant	Ant	Ant	Ant	Ant	Ant	Syn	Ant	Ant	Syn	Ant	
MN1	Ant	Ant	Ant	Ant	Ant	Syn	Ant	Ant	Ant	Ant	Syn	Ant	Ant	Ant	Ant	
PB1	Ant	Ant	Ant	Syn	Ant	Syn	Ant	Syn	Ant	Ant	Ant	Ant	Ant	Syn	Syn	
Total (syn)	1	1	3	4	3	8	4	3	6	5	10	5	5	0	11	7
Total (ant)	11	11	9	8	9	4	8	9	6	7	2	7	7	12	1	5

^a synergistic efficacy (β) of the below drug combination

^{b-d} whether the below drug/drug combination enhances the potency (synergistic) of TMZ, RT or gartisertib or does not enhance potency (antagonistic).

Abbreviations: antagonism (ant), synergy (syn), temozolomide (TMZ), RT (radiation)